Merck KGaA to design manufacturing process for first Nigerian vaccine plant through Innovative Biotech partnership
Merck will design the manufacturing process to help accelerate self-sufficient vaccine development and manufacturing in West Africa
Merck KGaA has agreed to design the manufacturing process for the first vaccine production facility in Nigeria through a collaboration with Innovative Biotech.
The partnership will initially focus on designing the fill and finish facility, incorporating the Merck KGaA’s Mobius single-use technology. The companies will then focus on enabling continuous manufacturing.
The deal is part of the West African pandemic readiness programme, which aims to develop high-quality and affordable vaccines locally in the African nations.
“We are proud to provide the technical support and expertise that could help enable the first vaccine facility in Nigeria and localize vaccine development in the West Africa region," said Andrew Bulpin, Head of Process Solutions, Life Science business sector at Merck KGaA.
TechnoVax — Innovative Biotech’s licensor — is developing a virus-like-particle (VLP)-based vaccine to target variants of COVID-19. Already, provisional results from the preclinical studies of the VLP-based vaccine have shown promise for virus neutralisation.
TechnoVax is a 2019 recipient of Life Science’s Advance Biotech Grant for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.
BioReliance, the life sciences business sector of Merck, has been supporting Innovative Biotech’s effort with its testing services, technical transfer support and single-use facility design.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.